Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
NCT07744763 SYS6041 Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07744763 SYS6041 Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07744763 clinical trial report covering SYS6041, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20262910 Bevacizumab biosimilar (Tot Biopharm) Colorectal Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20262910 Bevacizumab biosimilar (Tot Biopharm) Colorectal Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
CTR20262910 clinical trial report covering Bevacizumab biosimilar (Tot Biopharm), Phase 1/2, endpoints, sponsor, geography, readout timing and development
Read →
NCT07744256 EB-DART-NK01 Recurrent Lung Small Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07744256 EB-DART-NK01 Recurrent Lung Small Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07744256 clinical trial report covering EB-DART-NK01, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07743723 IOV-5001 Metastatic Solid Tumor Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07743723 IOV-5001 Metastatic Solid Tumor Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07743723 clinical trial report covering IOV-5001, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07743541 TUB-040 Recurrent Endometrial Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07743541 TUB-040 Recurrent Endometrial Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07743541 clinical trial report covering TUB-040, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07725432 Ruxolitinib Phosphate Vitiligo Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07725432 Ruxolitinib Phosphate Vitiligo Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07725432 clinical trial report covering Ruxolitinib Phosphate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07728019 Retlirafusp alfa Colorectal Liver Metastases Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07728019 Retlirafusp alfa Colorectal Liver Metastases Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07728019 clinical trial report covering Retlirafusp alfa, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07730580 Igermetostat Advanced Prostate Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07730580 Igermetostat Advanced Prostate Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07730580 clinical trial report covering Igermetostat, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07730151 Darolutamide Prostatic Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07730151 Darolutamide Prostatic Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07730151 clinical trial report covering Darolutamide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07733115 Iparomlimab/Tuvonralimab Intrahepatic Cholangiocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07733115 Iparomlimab/Tuvonralimab Intrahepatic Cholangiocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07733115 clinical trial report covering Iparomlimab/Tuvonralimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07734415 IMG-007 Eczema Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07734415 IMG-007 Eczema Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07734415 clinical trial report covering IMG-007, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07732634 Pembrolizumab Head and Neck Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07732634 Pembrolizumab Head and Neck Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07732634 clinical trial report covering Pembrolizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →